Bath scientists stabilise vaccine proteins with ensilication
A new system for delivering vaccines to children in low-income nations has taken a vital step forward, thanks to groundbreaking work at the University of Bath
Vaccines are notoriously difficult to transport to remote or dangerous places, as they spoil when not refrigerated. Formulations are safe between 2°C and 8°C, but at other temperatures the proteins start to unravel, making the vaccines ineffective. As a result, millions of children around the world miss out on life-saving inoculations.
However, scientists have now found a way to prevent warmed-up vaccines from degrading. By encasing protein molecules in a silica shell, the structure remains intact even when heated to 100°C, or stored at room temperature for up to three years.
The technique for tailor-fitting a vaccine with a silica coat – known as ensilication – was developed by a Bath team in collaboration with the University of Newcastle. This pioneering technology was seen to work in the lab two years ago, and now it has demonstrated its effectiveness in the real world too.
The researchers explain the significance of their findings
In their latest study, published in the journal Scientific Reports, the researchers sent both ensilicated and regular samples of the tetanus vaccine from Bath to Newcastle by ordinary post (a journey time of over 300 miles, which by post takes a day or two). When doses of the ensilicated vaccine were subsequently injected into mice, an immune response was triggered, showing the vaccine to be active. No immune response was detected in mice injected with unprotected doses of the vaccine, indicating the medicine had been damaged in transit.
Dr Asel Sartbaeva, who led the project from the University of Bath’s Department of Chemistry, said: “This is really exciting data because it shows us that ensilication preserves not just the structure of the vaccine proteins but also the function – the immunogenicity.”
“This project has focused on tetanus, which is part of the DTP (diphtheria, tetanus and pertussis) vaccine given to young children in three doses. Next, we will be working on developing a thermally-stable vaccine for diphtheria, and then pertussis. Eventually we want to create a silica cage for the whole DTP trivalent vaccine, so that every child in the world can be given DTP without having to rely on cold chain distribution.”
Cold chain distribution requires a vaccine to be refrigerated from the moment of manufacturing to the endpoint destination.
Silica is an inorganic, non-toxic material, and Dr Sartbaeva estimates that ensilicated vaccines could be used for humans within five to 15 years. She hopes the technology to silica-wrap proteins will eventually be adopted to store and transport all childhood vaccines, as well as other protein-based products, such as antibodies and enzymes.
“Ultimately, we want to make important medicines stable so they can be more widely available,” she said. “The aim is to eradicate vaccine-preventable diseases in low income countries by using thermally stable vaccines and cutting out dependence on cold chain.”
Currently, up to 50% of vaccine doses are discarded before use due to exposure to suboptimal temperatures. According to the World Health Organisation (WHO), 19.4 million infants did not receive routine life-saving vaccinations in 2018.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Covid news: UK reports 51,342 new infections; vaccines protect against new variant – as it happened
Latest figures come amid concern over spread of Omicron variant; Pfizer says third jab increased antibodies by factor of 25 ...
- CEOs and scientists on whether existing vaccines will work against Omicron
A preliminary study from Pfizer and BioNTech suggest that a booster shot might be the best way to combat Omicron.
- Our First Preview of How Vaccines Will Fare Against Omicron
In the eyes of vaccinated immune systems, Omicron looks like a big old weirdo—but also, a kind of familiar one. That’s the verdict served up by several preliminary studies and press releases out this ...
- Mixing vaccines boosts immune response; experimental saliva test nearly as accurate as PCR
They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.
- What We Know About Omicron and COVID Vaccines As Pfizer Says Booster Neutralizes Variant
Vaccine companies are testing their shots against the variant of concern—and some early data is beginning to emerge.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine
Boulder have demonstrated the feasibility of developing thermally-stable subunit protein vaccine formulations for filoviruses. The thermostabilized filovirus vaccine program is continuing to ...
- Swiss researchers working on new vaccines
A number of Swiss research groups are looking to develop new approaches to vaccines against coronavirus. The avenues being explored have included oral, bacterial spore-based and nasal sprays. Three ...
- All visitors must undergo thermal scanning per Uttar Pradesh’s new travel guidelines
According to the guidelines issued on December 2, all travellers coming into Uttar Pradesh will have to undergo thermal scanning ... SARS-CoV-2 virus has been fairly stable, which increases the ...
- How to get a job in vaccine development
We also need to make RNA vaccines that are more thermally stable; that way, they’d be more amenable for global roll-out, particularly in low- and middle-income countries. At Imperial ...
- Emerging Technologies Competition: Previous winners
Vaccines save millions of lives, but most are only stable when refrigerated ... fire-proof and sustainable Current insulation materials are either low-thermal-performance and non-combustible (mineral ...